Results 31 to 40 of about 15,580 (252)

Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany. [PDF]

Skin Health Dis
The TREATgermany registry was set up in 2016. We provide results on long-term dupilumab therapy in adults with moderate and severe atopic dermatitis (AD) in a routine care setting. The analysis cohort of 294 patients is one of the largest cohorts with 2-year follow-up data on treatment effects of dupilumab obtained from an AD registry to date.
Heinrich L, Birkner T, Abraham S, Gerdes S, Honstein T, Müller S, Augustin M, Harder I, Schaefer T, Pinter A, Bong A, Ramaker-Brunke J, Biedermann T, Sticherling M, Gorriahn-Maiterth H, Schäkel K, Schwarz B, Quist S, Asefi M, Adler N, Stahl M, Schulz-Kiesow M, Schenck F, Werfel T, Weidinger S, Heratizadeh A, Schmitt J.   +26 more
europepmc   +3 more sources

Level of serum galectin-10,STAT3 and CCL19 is correlated with disease severity in patients with chronic eczema [PDF]

Jichu yixue yu linchuang
Objective To investigate potential correlation of serum galectin-10(Gal-10), signal transducer, activator of transcription 3 (STAT3) and C-C chemokine ligand 19 (CCL19) with severity of chronic eczema.
MENG Xiaohui, JIANG Shiyao, YANG Yi
doaj   +1 more source

Mycosis fungoides found in patients with atopic dermatitis refractory to dupilumab; newly defined “eczematous mycosis fungoides”

, 2023
Supplementary table 1.
Kook, H (via Mendeley Data), Kook, Hyungdon   +1 more
core   +2 more sources

Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set and Recommended Instruments [PDF]

, 2020
The Harmonising Outcome Measures for Eczema (HOME) initiative has recommended a Core Outcome Set (COS) for atopic eczema clinical trials1. Adherence to this COS in future clinical trials of atopic eczema treatments will ensure outcomes are measured and ...
Ridd, MJ, Ridd, Matthew J, Vincent, R., Rogers, N., Chalmers, JR, Chalmers, Joanne R, Dodd, S., Ridd, M. J., Rodgers, N, Kirkham, J. J., McWilliams, C., Thomas, Kim S., Schmitt, J, Vincent, Rosie, Thomas, K. S., Kirkham, Jamie; id_orcid, McWilliams, C, KS, Thomas, Dodd, S, Chalmers, J. R., Rogers, N, Schmitt, J., Vincent, R   +22 more
core   +1 more source

Exploring the association between gastrointestinal heat retention syndrome and adult chronic eczema: A case–control study

Journal of Traditional Chinese Medical Sciences, 2020
Objective: To investigate the association between gastrointestinal heat retention syndrome (GHRS) and adult chronic eczema. Methods: This case–control study compared GHRS/GHRS accompanied by damp-heat syndrome (GHRS-DHS) and other patient characteristics
Chencheng Mei, He Yu, Wenlong Li, Xueyan Ma, Yunbi Zhang, Qi Sun, Yuhong Kong, Tiegang Liu, Teck Chuan Kong, Xiaohong Gu   +9 more
doaj   +1 more source

Ayurveda compound formulations “Panchatikta ghrita” and “Gandhakadya malahara” in the management of Vicharchika (atopic eczema): A prospective open-label clinical trial

International Journal of Ayurveda Research, 2023
Background: Eczema or atopic dermatitis is one of the significant public health concerns worldwide. Its prevalence is estimated to be 15–20% in children and 1–3% in adults.
Anil D. Avhad, Bhagwan Sahay Sharma, Sumedh N. Paikrao, Bidhan Mahajon, Shruti Khanduri, Arunabha Tripathi, Rakesh Rana, Richa Singhal, Kiran V. Kale, B.C.S Rao, Narayanam Srikanth   +10 more
doaj   +1 more source

Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study [PDF]

, 2019
Systemic treatment options for chronic hand eczema are limited. Dupilumab is used in atopic dermatitis (AD) but is not licensed for (isolated) hand eczema.
Romeijn, Geertruida L E, Schuttelaar, Marie L A, Oosterhaven, Jart A F, de Bruin-Weller, Marjolein S, Voorberg, Angelique N, MS Dermatologie/Allergologie, Infection & Immunity   +6 more
core   +3 more sources

Can serum biomarkers predict the outcome of systemic immunosuppressive therapy in adult atopic dermatitis patients?

Skin Health and Disease, 2022
Background Atopic dermatitis (AD or eczema) is a most common chronic skin disease. Designing personalised treatment strategies for AD based on patient stratification is of high clinical relevance, given a considerable variation in the clinical phenotype ...
G. Hurault, E. Roekevisch, M. E. Schram, K. Szegedi, S. Kezic, M. A. Middelkamp‐Hup, P. I. Spuls, R. J. Tanaka   +7 more
doaj   +1 more source

The Eczema Area and Severity Index

JEADV. Journal of the European Academy of Dermatology and Venereology
The Eczema Area and Severity Index is an investigator-assessed instrument reporting clinical signs of atopic dermatitis. The instrument is extensively validated in both adult and paediatric populations and recommended as a core outcome measure to assess clinical signs by the Harmonising Outcome Measures for Eczema initiative in clinical trials and was ...
Jacobson, M. E., Morimoto, R. Y., Leshem, Y. A., Howells, L., Williams, H. C., Grinich, E., Gerbens, L. A. A., Spuls, P. I., Schmitt, J., Staley, B., Baghoomian, W., Katoh, N., Thomas, K. S., Apfelbacher, C. J., Simpson, E. L.   +14 more
openaire   +3 more sources

Efficacy and safety of topical halometasone in eczematous dermatoses in Indian population: An open label, noncomparative study

Indian Journal of Dermatology, 2011
Background: Topical steroids remain the mainstay of treatment in eczema, an inflammatory skin reaction characterized by pruritus, redness, scaling, and clustered oozing papulovesicles.
H R Jerajani, A S Kumar, Maria Kuruvila, H V Nataraja, Mariam Philip, D V S Pratap, T K Sumathy, Binny Krishnankutty, Shilpi Dhawan, Dennis Thomas   +9 more
doaj   +1 more source